How to manage the transplant question in myelofibrosis

Blood Cancer Journal

Volumn 2, Issue 3, 2012, Pages

  Ballen, K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cord blood; Myelofibrosis; Transplantation

Indexed keywords

HYDROXYUREA; LENALIDOMIDE; PREDNISONE; THALIDOMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; DONOR; HUMAN; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; PROGNOSIS; RADIATION DOSE; REVIEW; SCORING SYSTEM; SPLENECTOMY; SPLENOMEGALY; SURVIVAL; TREATMENT FAILURE;

EID: 84864054446     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.3     Document Type: Review

References (46)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
2. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299-1307.
3. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097. (Pubitemid 47281402)
4. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018. (Pubitemid 26333326)
5. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
6. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSSPlus: a refined Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
7. Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011; 118: 4595-4598.
8. Cervantes F, Alvarez-Laran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Brit J Hematol 2004; 127: 399-403. (Pubitemid 39536591)
9. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158-1164. (Pubitemid 44232010)
10. Tefferi A. How I treat myelofibrosis. Blood 2011; 117: 3494-3504.
11. Tefferi A, Mesa RA, Nogomey DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226-2233. (Pubitemid 30167718)
12. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK 1 and JAK 2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
13. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF et al. A phase 2 trial of low-dose pomalidomide in myelofibrosis with anemia. Leukemia 2011; 25: 301-304.
14. Guardiola P, Anderson JE, Bandini G, Cervantes F, Funde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppos Italiano per il Trapianto Del Midollod Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831-2838. (Pubitemid 29200773)
15. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
16. Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Hematologica 2008; 93: 1514-1522.
17. Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO et al. Allogeneic hematopoeitic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Brit J Hematol 2010; 10: 1-9.
18. Zang DY, Deeg HJ. Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Curr Opin Hematol 2009; 15: 140-146.
19. Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia, and Philadelphia negative/bcr-abl negative chronic myelogeneous leukemia. Bone Marrow Transplant 2004; 3: 1005-1009. (Pubitemid 38744786)
20. Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004; 34: 807-813. (Pubitemid 39467893)
21. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic transplantation for myelofibrosis. Blood 2003; 102: 3912-3918.
22. Kerbauy DM, Gooley TM, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355-365.
23. Daly A, Song K, Nevill T, Nantel S, Toze C, Hogge D et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003; 32: 35-40. (Pubitemid 36850278)
24. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. (Pubitemid 28078275)
25. Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 604-612. (Pubitemid 33130593)
26. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637. (Pubitemid 32113394)
27. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255-2258. (Pubitemid 34525517)
28. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119. (Pubitemid 40656163)
29. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwedtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
30. Merrup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Brit J Hematol 2006; 135: 367-373. (Pubitemid 44484845)
31. Snyder DS, Palmer J, Gaal K, Pullarkat V, Sahebi F, Cohen S et al. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 281-286.
32. Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation Study. Bone Marrow Transplant 2010; 45: 1587-1593.
33. Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Brit J Hematol 2011; 153: 76-82.
34. Ballen KK, Spitzer TR. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant 2011; 46: 323-329.
35. Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey B, Attar E et al. Double unrelated reduced intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82-89. (Pubitemid 46044092)
36. Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood 2010; 116: 649-652.
37. Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT et al. Allogeneic hematopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size, and donor type. Bone Marrow Transplant 2010; 45: 458-463.
38. Scott BL, Gooley TA, Linenberger ML, Sandmaier BM, Myerson D, Chauncey T et al. International Working Group scores predict post-transplant outcomes in patients with myelofibrosis. Blood 2010; 116: 965a (abstract).
39. Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonade S, Dobogai LC et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Brit J Hematol 2008; 141: 80-83. (Pubitemid 351350607)
40. Akpek G, Pasquini MC, Agovi MA, Logan B, Cooke KR, Maziarz RT et al. Spleen status and engraftment after allogeneic hematopoietic stem cell transplantation. Blood 2010; 116: 3486a.
41. Robin M, Esperous H, Peffault R, Petropoulou AD, Xhaard A, Ribauad P et al. Splenectomy after allogeneic hematopoietic stem cell transplantation in patients with primary myelofibrosis. Brit J Hematol 2010; 150: 721-724.
42. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572-3581.
43. Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH. Use of the activating gene mutation of the tyrosine kinase JAK2 as a minimal disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007; 83: 1518-1520. (Pubitemid 46934078)
44. Tefferi A. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplant 2010; 45: 419-421.
45. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008; 22: 474-486. (Pubitemid 351386717)
46. Vaidya R, Caramazza C, Begna KH, Gangat N, VanDyke DL, Hanson CA et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood 2011; 117: 5612-5615.